Vaccines

Biological E joins the ranks of Pfizer, GSK and Serum with WHO prequalification for its pneumococcal vaccine. As WHO's purchase data for Serum’s PSV10 indicate significant opportunity, Scrip spoke to Biological E on supply readiness and its application for exemption from price control in India

Reduced immunization rates in the US marred the results of both GSK and Merck, but with Merck’s biggest drug approaching its loss of exclusivity, lower vaccine sales and sluggish new product revenues spooked investors. GSK left more room for optimism.

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

CSL Limited said during its annual meeting that with US influenza vaccination rates down 12%-14%, it will delay the separation of its vaccine business Seqirus beyond the end of financial year 2026.

Dupixent revenues were a record €4.16bn but the “negative buzz around vaccines” is hurting flu sales, according to chief financial officer François Roger.

The company is discontinuing congenital CMV development for its mRNA-1647 vaccine but still running a Phase II trial in bone marrow transplant patients.

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Doors open at £150m vaccine facility which forms part of a £1bn investment in the country on the part of Moderna, as other firms head for the exit.

New cash will increase its total assets under management to over $1.4bn.

The US political environment and vaccine hesitancy by the general population have affected the sale of safe vaccines with clinical utility and no competition. The confusion and contradictions in the recent ACIP meeting are likely to stoke these pressures further.

Indian firms are upping indigenization, exploring AI application and expanding use of technology platforms like self-amplifying mRNA to develop vaccines against age-agnostic diseases like malaria, dengue, flu and Nipah encephalitis

The companies said preliminary data showed a fourfold increase in LP.8.1-neutralizing antibody titers from the latest formula of Comirnaty, which the FDA approved last month.